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 2 
Summary 14 
BACKGROUND 15 
Previous studies have suggested that fluoxetine could improve neurological recovery after 16 
stroke. The EFFECTS trial was designed to test the hypothesis that administration of 17 
fluoxetine for 6 months after acute stroke would improve functional outcome. 18 
METHODS 19 
EFFECTS was an investigator-led, parallel group, randomised, placebo-controlled trial that 20 
enrolled non-depressed stroke patients aged 18 years or older between two and 15 days after 21 
stroke onset in 35 hospitals in Sweden. The patients had a clinical diagnosis of ischemic or 22 
intracerebral haemorrhage with persisting focal neurological deficits at inclusion. A web-23 
based randomisation system which incorporated a minimisation algorithm was used to 24 
allocate participants to fluoxetine 20 mg once daily or matching placebo capsules for 6 25 
months with a ratio of 1:1. Patients, care providers, investigators, and outcomes assessors 26 
were masked to the allocation. The primary outcome was functional status, measured with the 27 
modified Rankin Scale (mRS) at 6 months. Patients were analysed according to their 28 
treatment allocation. EFFECTS is registered with ClinicalTrials.gov, number NCT02683213. 29 
FINDINGS 30 
Recruitment started 20 Oct 2014 and ended 28 June 2019, when the planned 1500 patients 31 
were included (750 to fluoxetine and 750 to placebo). mRS data were available for 737/750 32 
(98%) in the fluoxetine group and 742/750 (99%) in the placebo group. The primary outcome 33 
- distribution across mRS categories– was neutral (common odds ratio adjusted for 34 
minimisation variables 0·98 [95% CI 0·91 to 1·05], p=0·55). Fluoxetine reduced depression 35 
(54 [7∙2%] patients vs 81 [10·8%]; difference -3∙6% [95% CI -0·065 to -0·0071]; p=0∙015) 36 
but was associated with more bone fractures (28 [3∙7%] vs 11 [1∙5%]; difference 2∙2% [95% 37 
CI 0·0066 to 0·039]; p=0∙0058) and hyponatremia (11 [1∙47%] patients vs 1 [0·13%]; 38 
  
 
 3 
difference 1∙34% [95% CI 0·0043 to 0·022]; p=0∙0038). There were no treatment-related 39 
deaths. 40 
INTERPRETATION 41 
Functional outcome after acute stroke did not improve with fluoxetine 20 mg once daily for 6 42 
months. Fluoxetine reduced the occurrence of depression but increased the risk of bone 43 
fractures and hyponatraemia. Our results do not support the routine use of fluoxetine after 44 
acute stroke. 45 
FUNDING 46 
The Swedish Research Council, the Swedish Heart-Lung Foundation, the Swedish Brain 47 
Foundation, the Swedish Society of Medicine, King Gustav V and Queen Victoria’s 48 
Foundation of Freemasons, and the Swedish Stroke Association (STROKE-Riksförbundet).  49 
Key words  50 
Stroke, fluoxetine, selective serotonin reuptake inhibitor, SSRI, stroke recovery, recovery of 51 
function, EFFECTS 52 
Introduction  53 
Worldwide, stroke affects 13·7 million people each year1 and approximately half of all 54 
survivors are left with disability. 2 Whereas major advances have been made in acute 55 
treatment, there is a need for new treatments focused on long-term stroke recovery 56 
irrespective of eligibility for acute treatments. One possible drug is fluoxetine, a selective 57 
serotonin reuptake inhibitor (SSRI). SSRIs has been widely used for more than three decades 58 
to treat several hundred million people with mood disorders. A meta-analysis of animal stroke 59 
models has shown that fluoxetine improves neurobehavioral outcomes by 52%, probably by 60 
enhancing neuroplasticity. 3  In 2011, the FLAME trial (n=118) reported promising results for 61 
stroke recovery. 4 FLAME randomised ischaemic stroke patients to 20 mg fluoxetine daily or 62 
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placebo (ratio 1:1) for 3 months. The proportion of independent was 17 absolute percent 63 
higher in the fluoxetine group (26% versus 9%, p=0·015). 64 
In a Cochrane review of SSRIs for stroke recovery from 2012, SSRIs appeared to reduce 65 
disability after ischaemic or intracerebral haemorrhage. 5 However, the review found 66 
heterogeneity between trials and methodological limitations in a sizable proportion of the 67 
studies; most were small and prone to systematic and random errors. The authors called for 68 
large, well-designed trials of SSRIs and stroke recovery. Three trial investigator teams 69 
collaboratively developed a core protocol but the trials were funded and run independently. 6,7 70 
Minor variations were tailored to the national settings in the UK (Fluoxetine Or Control 71 
Under Supervision [FOCUS]), Australia, New Zealand, and Vietnam (Assessment oF 72 
FluoxetINe In sTroke recoverY [AFFINITY]), and Sweden (Efficacy of Fluoxetine–A 73 
Randomised Controlled Trial in Stroke [EFFECTS]). The AFFINITY trial results are reported 74 
in a parallel publication. 8 75 
 76 
In December 2018, FOCUS (n=3127) published its results. 9 The primary outcome – the 77 
distribution across mRS categories at 6 months – was neutral. Patients allocated fluoxetine 78 
were less likely than placebo to develop new depression by 6 months (13·4% versus 17·2%, 79 
p=0·0033), but they had more bone fractures (2·9% versus 1·5%]; p=0·007). The adherence to 80 
study medication was moderate. One in three took the trial medication for less than 150 of the 81 
prescribed 180 days, which might reduce the generalisability of the FOCUS results outside 82 
the UK. 83 
EFFECTS hypothesised that administration of fluoxetine for 6 months after acute stroke in 84 
Sweden would improve functional outcome. 85 
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Methods 86 
Study design and patients 87 
EFFECTS was an investigator-led multicentre, randomised, placebo-controlled, parallel 88 
group trial of fluoxetine for stroke recovery. Eligible patients were identified from stroke and 89 
rehabilitation units in Sweden (appendix, p 12-15). The study protocol was approved by a 90 
central medical ethics committee in Stockholm (reference 2013/1265-31/2, date: 03/09/2013) 91 
and by the Swedish Medical Agency (reference 5.1-2014-43006, date 08/08/2014). All 92 
patients provided written informed consent before randomisation. Consent from relatives was 93 
not accepted. The protocol6, statistical analysis plan7, and an update on the amendment to the 94 
protocol10 have been published. All inclusion and exclusion criteria are listed in the appendix 95 
p 3. Briefly, patients were eligible if brain imaging was compatible with intracerebral 96 
haemorrhage or ischaemic stroke, randomisation was possible between two and 15 days after 97 
stroke onset, and the patient had persisting focal neurological deficit(s) severe enough to 98 
warrant treatment with the investigational medicinal product for six months from the 99 
perspective of the randomising physician AND patient. Patients were excluded if they had a 100 
primary subarachnoid haemorrhage; were unlikely to be available for follow-up for the next 101 
12 months; had a history of epileptic seizures; previous drug overdose or attempted suicide; 102 
or an ongoing depression. Patients on anti-depressant medication – regardless of indication – 103 
were also excluded. Other exclusion criteria were allergy or contraindication to fluoxetine; or 104 
medication(s) which could have a serious interaction with fluoxetine; hepatic impairment 105 
(alanine aminotransferase more than three times the upper normal limit) and renal impairment 106 
(creatinine > 180 mol/L); pregnancy or breastfeeding.  107 
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Randomisation and masking 108 
EFFECTS shared the randomisation system with the FOCUS trial. 9 After obtaining written 109 
informed consent, a medical doctor or nurse entered data into a secure web-based 110 
randomisation system. The system checked data for completeness and consistency and 111 
allocated the patient an ID and a treatment number. Patients were randomised in a 1:1 ratio to 112 
either fluoxetine 20 mg once daily or placebo for 6 months. We tested 20 mg daily which was 113 
the dose used in most previous trials of fluoxetine in stroke. 114 
The system applied a minimisation program to achieve balance for four factors: 115 
1) Delay since stroke onset (2–8 versus 9–15 days) 116 
2) Predicted 6 months outcome based on the six simple variable (SSV) model 11 117 
3) Presence of a motor deficit based on National Institutes of Health Stroke Scale12 118 
(NIHSS) at inclusion 119 
4) Presence of aphasia based on NIHSS at inclusion.  120 
The SSV included six variables, four at the onset and two prior to the stroke. Onset variables 121 
were: age; ability to walk unassisted; ability to talk; and whether confusion is present or not. 122 
The two variables before stroke were whether the patient was independent and living alone. 123 
Details how to calculate the SSV is given in appendix page 4. The randomisation system was 124 
set up so that the investigator could not the next assignment in the sequence. The 125 
minimisation algorithm 13 randomly allocated the first patient to treatment, but each 126 
subsequent patient was allocated to the treatment that lead to the least difference between the 127 
treatment groups with respect to the prognostic factors. To ensure a random element to 128 
treatment allocation, patients were allocated to the group which minimised differences 129 
between groups with a probability of 0·8. 130 
The placebo capsule was visually identical to the fluoxetine capsules, even when broken 131 
open. Patients, their families, health-care personnel, staff in the coordinating centre 132 
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(Karolinska Institutet, Department of Clinical Sciences Danderyd Hospital), and the 133 
pharmacy were masked to treatment allocation. 134 
An emergency unblinding system was available but was designed so that the co-ordinating 135 
centre and those doing follow-up continued to be masked throughout the study.  136 
Procedures 137 
The intervention was initiated as soon as possible after the randomisation. We did not titrate 138 
the dose; we recommended the patient take it in the morning. The study medication 139 
(intervention and placebo) was made by Unichem (Goa, India), imported by Niche Generics 140 
Ltd (Hitchin, UK), bought from Discovery Pharmaceuticals Ltd (Castle Donington, UK), and 141 
quality assured, packaged, labelled, and distributed by Sharp Clinical Services to Apoteket 142 
AB in Sweden. 143 
At the local centre, the trial medication was prescribed on the patient’s medication chart as 144 
“EFFECTS trial medication (fluoxetine 20 mg/placebo), one capsule daily, orally (or enteral 145 
tube if unable to swallow) for 6 months”. The study medication was dispensed for the first 146 
three months, 100 capsules, Bottle #1. The rationale for 100 capsules, was to have some in 147 
reserve, in case of delayed follow-up. When the patient was discharged, the trial medication 148 
was continued and documented on the discharge summary as well as on the patient’s list of 149 
ongoing medication. After a little less than three months, the patient was given the last 100 150 
capsules (Bottle #2) at a face-to-face follow-up at the local centre. Patients were instructed to 151 
bring Bottle #1 to this follow-up. When a patient could not attend a face-to-face meeting, the 152 
study medication was posted to them. The study drug was free of charge. 153 
Patients who stopped taking the allocated treatment early were followed-up and their data 154 
were included in the primary analyses. The reason for stopping the treatment prematurely, for 155 
instance due to a Serious Adverse Event was recorded in the patient’s electronic Case Report 156 
Form. 157 
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 158 
Each centre was reimbursed with 5000 SEK (375 GBP) per patient and supplied with 159 
medical record templates for inclusion as well as a template letter to inform Family 160 
Physicians about the trial. 161 
If a patient was judged to have developed new clinical depression during follow up, we 162 
recommended that the patient stay on the study medication and add 15 mg mirtazapine, with 163 
the possibility of titrating up to 45 mg mirtazapine. If 45 mg mirtazapine did not work, we 164 
recommended adding 20 mg fluoxetine.  165 
Outcomes 166 
Details of the outcomes and definitions are described in the appendix. In summary, the 167 
primary outcome was functional status at 6 months (± 14 days), measured using the modified 168 
Rankin scale (mRS). 14 We used the simple modified Rankin scale questionnaire15,16 (smRSq) 169 
delivered by postal questionnaire or via interview over the telephone to derive the mRS score. 170 
 171 
Centrally (i.e. at the trial coordinating centre based at Danderyd Hospital), we collected the 172 
following secondary outcomes – also common to FOCUS and AFFINITY – by mail at 6 173 
months: survival; the Stroke Impact Scale v. 317,18 (SIS), to provide an overall assessment of 174 
patient outcome as well as allowing us to assess the effect of treatment on specific outcomes 175 
of importance to the patients; and what medications – if any – the patient was on. All 176 
responses received were screened by the Trial Manager Assistant, an experienced research 177 
nurse. If there were missing data, inconsistent answers, or we did not receive a reply within 178 
two weeks, the Trial Manager Assistant called the patient or next of kin to complete the 179 
answers by telephone.  180 
In addition, we collected the following secondary outcomes 3 and 6 month face-to-face 181 
follow-ups: National Institutes of Health Stroke Scale12 (NIHSS) to assess stroke severity as 182 
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well as motor function and aphasia; Montreal Cognitive Assessment19 (MoCA), to assess the 183 
patients’ cognitive function; new diagnosis of depression since randomisation (Diagnostic 184 
and Statistical Manual of Mental Disorders20 (DSM-IV) criteria, and Montgomery-Åsberg 185 
Depression Rating Scale21 (MADRS) ); adverse events; and safety outcomes (see appendix 186 
p 10 for definition). The psychiatric evaluation regarding depression was done by the local 187 
physician, a medical doctor. In case of uncertainty, a psychiatrist was consulted. Adherence 188 
was measured at 1 week (± 3 days), 1 month (± 7 days), 3 months (± 7 days), and 6 months (± 189 
14 days), by asking the patient, carer or health personnel how often the patient took the study 190 
medication.  191 
The research nurses counted the capsules returned and recorded this in the case report form. 192 
Adherence was defined as taking the study medication 5-7 days/week. Intermediate 193 
adherence was defined as taking the study medication 1-4 days/week or with some 194 
interruptions (Supplementary table h, appendix). 195 
 196 
We have reported a majority of the prespecified secondary outcome in the present paper. 197 
Analysis of physical activities and health economics including quality of life is ongoing. 198 
Extensive information of depressive symptoms is to be reported later. The last 12 months 199 
follow-up is planned December 2020. In addition, we are going to follow-up all patients in 200 
national registries up to at least 3 years. 201 
Statist ical analysis 202 
All outcomes were prespecified and described in detail in our published statistical analysis 203 
plan.7 Enrolment of 1500 patients randomised 1:1 aimed to provide 90% power to detect a 204 
5·6% absolute increase in the proportion with mRS 0–2 from, 27·0% to 32·6% based on an 205 
ordinal analysis. We hypothesised that an absolute difference of 5·6% would represent a 206 
clinically meaningful effects size for patient and society. For the primary analysis, we used 207 
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the common odds ratio with 95% confidence interval (CI), adjusted for factors in the baseline 208 
minimisation. We chose an ordinal analysis since it is considered more efficient than 209 
dichotomised analysis. 22 When secondary outcomes were binary, we used logistic regression, 210 
and presented the results as common odds ratio with 95% CIs, absolute and relative risk 211 
reduction. When variables were continuous, we used descriptive statistics, and when 212 
comparing the two groups, we used the Mann-Whitney test. We used intention-to-treat 213 
analysis. All analysis, except the primary outcome, are un-adjusted. Statistical analyses were 214 
done with SAS for Windows, version 9.4. 215 
 216 
The unmasked trial statistician prepared analyses of the accumulating data for the Data 217 
Monitoring Committee according to a specific plan. No other person had access to these 218 
analyses. If we could not get any answer by mail, telephone, face-to-face follow-up, or 219 
registry the corresponding variable was set to missing. The steering committee did not do any 220 
interim analysis. 221 
 222 
EFFECTS is registered with EudraCT, number 2011-006130-16; ISRCTN, number 223 
13020412; and ClinicalTrials.gov, number NCT02683213. 224 
Role of the funding source  225 
The funders of the study had no role in study design, data collection, data analysis, data 226 
interpretation, or writing of the report. The corresponding author had full access to all the data 227 
in the study and had final responsibility for the decision to submit for publication. All funders 228 
are non-commercial, with none from industry. The sponsor was Karolinska Institutet, 229 
Department of Clinical Sciences, Danderyd Hospital, 182 88 Stockholm, Sweden. The 230 
sponsor’s representative was EL. 231 
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Results 232 
Recruitment in EFFECTS started 20 October 2014 and ended 28 June 2019 when the planned 233 
target was reached. A total of 1500 patients were included from 35 Swedish centres. The last 234 
6 months follow-up was on 17 December 2019. Half of the enrolled patients were allocated 235 
fluoxetine (figure 1). 236 
Of 3753 patients assessed for eligibility, 2253 were excluded (1547 did not meet inclusion 237 
criteria; 394 declined participation; and 312 were not recruited for other reasons). EFFECTS 238 
randomised 1500 patients (750 placebo and 750 placebo). After randomisation, 11 patients 239 
did not meet our eligibility criteria (protocol violators). Three had a final diagnosis other than 240 
stroke (two in fluoxetine and one in placebo), six patients had antidepressant at randomization 241 
(three in each group), and two patients randomised at day 16 (one in each group). In two 242 
cases (one in each group), the Family Physicians prescribed fluoxetine instead of just 243 
continuing on the study medication. The patient allocated placebo (crossover), were on 244 
fluoxetine approximately between 3 and 6 months. We unmasked one patient who developed 245 
symptoms of bipolar disorder. The psychiatrist responsible argued that knowledge of the 246 
allocation would substantially alter the management of the patient. The patient was allocated 247 
to placebo. Ineligible patients were retained in the intention-to-treat analyses. The number of 248 
patients assessed for the primary outcome, was 737 for fluoxetine and 742 for placebo. 249 
 250 
  Insert figure 1 here. 251 
 252 
Baseline characteristics include: ischemic stroke 1312 (87·4%); intracerebral haemorrhage 253 
185 (12·3%); non-stroke 3 (0·2%); mean age 70·8 (10·9) years; female 575 (38·3%); 254 
previously independent 1445 (96·3%); median NIHSS score 3·0 (2·0, 6·0) points; and 255 
presence of motor deficit 1046 (69·8%). The two treatment groups were well balanced (table 256 
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1) at baseline, and similar to a Swedish stroke population according to Riksstroke regarding 257 
age, risk factors, proportion ischemic vs intracerebral haemorrhage, and stroke severity, 258 
measured with NIHSS. 23 EFFECTS had a lower proportion of women and a slightly lower 259 
number of independent before stroke (appendix p 18), compared to Swedish stroke 260 
population. 23 261 
 262 
Insert table 1 here 263 
 264 
Figure 2 shows the distribution of the mRS in the treatment and control group. The trial was 265 
neutral with respect to the primary outcome – functional status measured with mRS at 6 266 
months (common odds ratio adjusted for minimisation variables 0·978 [95% CI 0·910 to 267 
1·052]; p=0·55); figure 2. 268 
 269 
  Insert figure 2 here. 270 
 271 
Patients allocated fluoxetine scored lower on memory and higher on emotion on the SIS 272 
(table 2). There was no difference in NIHSS and MoCA scores (table 2). 273 
 274 
Insert table 2 here. 275 
 276 
Fewer patients treated with fluoxetine had new depression (54 [7·2%] vs 81 [10·8%]; 277 
p=0·015); difference in proportions -3·6% [95% CI -0·065 to -0·0071]; p=0·015 (table 3) and 278 
uncontrolled diabetes. However, patients allocated fluoxetine had an increased risk of bone 279 
fractures (28 [3·7%] patients vs 11 [1·5%]; difference in proportions 2·2% [95% CI 0·0066 to 280 
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0·039]; p=0·0058), and hyponatraemia (11 [1∙47%] patients vs 1 [0·13%]; difference 1∙34% 281 
[95% CI 0·0043 to 0·022]; p=0∙0038) (table 3). There were no treatment-related deaths. 282 
 283 
Insert table 3 here. 284 
 285 
The prespecified subgroup analyses are available in the appendix p 20. There was no 286 
significant interaction between the subgroups and the effect on the primary outcome. 287 
 288 
Adherence to fluoxetine and placebo was very high. At 1 week, 1 month, 3 months, and 6 289 
months the adherence to fluoxetine was 96% (703/730), 91% (658/721), 88% (630/722), and 290 
89% (594/666), respectively. The adherence was almost identical for placebo: 94% 291 
(693/735), 93% (682/736), 86% (622/727), and 89% (595/673), respectively appendix p 21. 292 
Our monitors cross-checked the counting for 10% of the patients.10 Our monitors cross-293 
checked the counting for 10% of the patients.10 The median duration of treatment was 180 294 
days (IQR 180–180) for both groups. About 89% (1338/1500) took the study medication for 295 
at least 150 days. 296 
The most common reason for stopping the study medication was perceived side effects; in the 297 
fluoxetine group 8·3% (62/750) stopped within the first 90 days compared with 8·8% 298 
(66/750) in the placebo group. 299 
 300 
Discussion 301 
EFFECTS is the second largest randomised controlled (RCT) of fluoxetine for stroke 302 
recovery. Fluoxetine 20 mg once daily after an acute stroke did not improve patients’ 303 
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functional outcome at 6 months. However, depression was reduced and emotional scores on 304 
the SIS were improved with fluoxetine. Fluoxetine increased bone fractures. 305 
 306 
EFFECTS has several strengths. Firstly, we reduced bias by central randomisation and 307 
masking of treatment for patients, care providers, investigators, and outcome assessors. Only 308 
one patient (0·067%) was unmasked. Secondly, we minimised random error with a large 309 
sample size and high follow-up (≥98% for the primary outcome). Thirdly, we had high 310 
adherence, 89% at 6 months.  311 
 312 
In comparison to FOCUS, EFFECTS added face-to-face follow-up at 6 months. This enabled 313 
us to include NIHSS, MoCA, and careful estimation of depression. The NIHSS scores were 314 
identical between the groups, a result that points in the same direction as a neutral mRS. The 315 
results on memory and cognition were conflicting. Patients allocated fluoxetine scored lower 316 
on the SIS domain for memory, but both groups had similar MoCA scores. Since MoCA is a 317 
more comprehensive test of memory, and the results in FOCUS were neutral on memory, 318 
fluoxetine probably does not affect cognition. 319 
 320 
The occurrence of depression was lower in EFFECTS, compared to FOCUS, which could be 321 
attributed to another way of measuring depression or the fact that FOCUS included more 322 
severe strokes. 323 
 324 
The external validity of our results is also supported by the fact that we included patients 325 
from 35 centres in Sweden with similar baseline characteristics as in Riksstroke23 regarding 326 
stroke type, severity, and independency before stroke. Further confirmation of external 327 
validity is the fact that we observed similar results to FOCUS 9  and AFFINITY 8; neutral 328 
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results for the primary outcome but reduction of depression. FOCUS had a population with 329 
more severe strokes (median NIHSS of 6) compared to the median NIHSS of 3 for 330 
EFFECTS.  331 
Finally, our results are also in line with the updated version of the Cochrane review of SSRIs 332 
for stroke recovery from 2019.24 When including only low bias RCTs, SSRIs do not improve 333 
recovery from stroke. 334 
 335 
Safety  outcome 336 
The absolute excess risk of 2·2% of bone fractures in EFFECTS is consistent with FOCUS 337 
and previous reports from large case-control and cohort studies. 25 Serotonin receptors are 338 
found in all major types of bone cell, and the use of SSRIs has been linked to reduced bone 339 
mineral density.26 This increased risk is highest after initiation, with a peak at 8 months for 340 
SSRI. 26 341 
Except for an increased risk of bone fractures and hyponatraemia, fluoxetine seems to be a 342 
reasonably safe drug in the stroke population. Gastrointestinal bleeding and thrombotic 343 
adverse events were similar between the groups, despite fluoxetine’s known effect on platelet 344 
function and interaction between fluoxetine and antiplatelet and anti-coagulant medication. In 345 
EFFECTS, fluoxetine did not increase the number of epileptic seizures. Our finding of better 346 
diabetes control for patients allocated fluoxetine compared to placebo is unexpected. Rather, 347 
the reverse was expected due to the known side effects of fluoxetine We interpret the results 348 
as a chance finding due to random error associated with multiple analyses. 349 
Limitat ions 350 
EFFECTS has several limitations that affect its generalisability. Firstly, EFFECTS had a 351 
higher proportion of men enrolled (62%). This male predominance of men in stroke studies is 352 
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a known but unexplained observation. 27 Secondly, it was performed in only one country, 353 
Sweden. Healthcare systems vary between countries, and it is not certain that results from 354 
high-income countries are directly transferable to low and middle-income countries. Thirdly, 355 
in EFFECTS, we included patients with persisting focal neurological deficit present at the 356 
time of randomisation severe enough to warrant treatment from the physicians and the 357 
patient’s perspective. In our power calculation we expected 27% of the control group to have 358 
mRS 0–2. It turned out that we had more than double the number (64%) of stroke with mRS 359 
0–2 in the control group.  Effectively, we ended up with a median NIHSS of three, and we 360 
cannot exclude that patients with a more severe stroke may benefit from fluoxetine. Fourthly, 361 
we could have included the Fugl-Meyer scale, a more sensitive motor scale used in the 362 
FLAME trial, since we did a face-do-face follow-up at 6 months (unlike FOCUS and 363 
AFFINITY trial). Although the scale is invented in Sweden, it is not used by all hospitals in 364 
our country, and we wanted to keep the study as simple as possible. 365 
Finally, our use of the smRSq to calculate the mRS could be regarded as a limitation. The 366 
validity and reliability of the smRSq has been tested and found to be high.15,16 Recently, a 367 
study of 3204 patients from the ENCHANTED trial showed good agreement between smRSq 368 
and mRS scores.28 Reassuringly, the results for ENCHANTED were similar using smRSq 369 
compared to mRS face-to-face. In EFFECTS, it was important that data could be collected by 370 
mail or telephone. Also, it was important to use the same primary outcome as our sister trials 371 
FOCUS and AFFINITY to allow for the future pooling of individual patient data. 372 
 373 
In summary, EFFECTS show that fluoxetine 20 mg given once daily for 6 months after an 374 
acute stroke did not improve patients’ functional outcomes but did decrease depression. Our 375 
results do not support the routine use of fluoxetine to improve outcome or to prevent post-376 
stroke depression. The results from the planned individual patient data meta-analysis are 377 
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required to confirm or refute a more modest benefit or harm. Until these results are published, 378 
we do not recommend further fluoxetine trials for stroke recovery.  379 
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Titles and Legends for Tables 494 
Table 1. Patient characteristics at randomisation. 495 
Legend table 1: Data are n (%), mean (SD), or median (IQR). TIA=Transient Ischaemic 496 
Attack. OCSP=Oxfordshire Community Stroke Project. NIHSS=National Institutes of Health 497 
Stroke Scale. * One point or more on item 4 (Facial palsy) or, item 5 (Left or right arm motor 498 
drift) or, item 6 (Left or right leg motor drift) on NIHSS. † One point or more on NIHSS item 499 
9 (Language/aphasia). 500 
Non-strokes were in the fluoxetine group 1 primary subarachnoid haemorrhage, and 1 501 
hydrocephalus; in the placebo group 1 cerebral tumour. 502 
‡ The medical history was verified by the medical doctor using all available information at 503 
that time of randomisation. There was unknown prior medical history for 6 coronary artery 504 
diseases; 2 ischaemic stroke/TIAs; 2 diabetes; 19 hyponatraemias; 2 intracranial bleeds; 9 505 
upper gastrointestinal bleeds; 14 bone fractures; 6 depressions respectively. 506 
** There were 726 valid cases for the fluoxetine group, and 731 for placebo. 507 
 508 
Table 2. Secondary outcomes at 6 months by allocated treatment. 509 
Legend table 2: *N denotes the number of patients with each of the secondary outcome 510 
scores. Data were only available for those who survived and who completed sufficient 511 
questions to derive a score. Data are median (IQR). Stroke Impact Scale v. 3.0 has a score 512 
between 0–100, where higher scores indicated better function. P-value=Mann-Whitney. 513 
†Mean of the Strength, Hand ability, and Mobility domains. ‡Mean of the Strength, Hand 514 
ability, Mobility, and Daily activities domains. NIHSS=National Institutes of Health Stroke 515 
Scale. MoCA=Montreal Cognitive Assessment. 516 
 517 
Table 3. Safety outcomes within 6 months. 518 
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Legend table 3: Data are n (%), unless otherwise stated. All variables in this table are pre-519 
specified safety outcomes. Antidepressant drug refers to treatment outside study medication. 520 
Other thrombotic events included 9 Transient Ischaemic Attacks, 1 central retinal artery 521 
occlusion, and 1 cerebral venous thrombosis. Other major bleed was defined as a bleeding 522 
that was reported by the local centre as a Serious Adverse Event. Details of the 11 major 523 
bleedings are given in Supplementary table i, and cause of death in Supplementary table j 524 
(appendix p 21-22). 525 
Titles and Legends for Figures 526 
Figure 1: Trial profile. 527 
Legend figure 1: mRS=modified Rankin Scale. 528 
 529 
Figure 2: Primary outcome, the modified Ranking Scale at 6 months. 530 
Legend figure 2: Data are n above the bars and % inside the bars. There was 98% (737/750) 531 
modified Rankin Scale (mRS) data available in the fluoxetine, and 99% (742/750) in the 532 
placebo group. Patients in the fluoxetine group received one capsule of 20 mg fluoxetine per 533 
day in 6 months plus standard care. Patients in placebo group received a matching placebo 534 
capsule 6 months plus standard care. The mRS range from 0 to 6, with mRS 0 indicating no 535 
symptoms, mRS 1 no clinically significant disability, mRS 2 slight disability, mRS 3 536 
moderate disability, mRS 4 moderately severe disability, mRS 5 severe disability, and mRS 6 537 
death. 538 
 539 
Research in context  
Evidence before th is s tudy 
The majority of patients with stroke are left with residual symptoms. The hope that selective 
serotonin reuptake inhibitors (SSRIs) may improve recovery was initiated in experimental 
stroke models and ignited by the FLAME trial (n=118) published in 2011 which showed 
improvement in motor function at 3 months. 
In 2012 we did a Cochrane review of SSRIs for stroke recovery which included randomised 
controlled trials that recruited stroke survivors (ischaemic or haemorrhagic) at any time within 
the first year. The intervention was any SSRI, given at any dose, for any period. We searched 
the Cochrane Stroke Group Trials Register (August 2011), Cochrane Depression Anxiety and 
Neurosis Group Trials Register (November 2011), Cochrane Central Register of Controlled 
Trials (CENTRAL) (The Cochrane Library 2011, Issue 8), MEDLINE (from 1948 to August 
2011), EMBASE (from 1980 to August 2011), CINAHL (from 1982 to August 2011), AMED 
(Allied and Complementary Medicine) (from 1985 to August 2011), PsycINFO (from 1967 to 
August 2011) and PsycBITE (Psychological Database for Brain Impairment Treatment 
Efficacy) (March 2012), trial registers, pharmaceutical websites, reference lists, contact with 
experts and citation tracking of included studies). We included the standard Cochrane search 
terms for randomised controlled trials and stroke, SSRIs (as a group) or the individual SSRIs. 
All languages were included. Fifty-six completed trials of SSRI versus control, of which 52 
trials (4060 participants) provided data for meta‐analysis. At the end of treatment, the relative 
risk for reducing dependency was 0·81 (95% CI 0·68 to 0·97; one trial); and for disability 
score, the standardized mean difference was 0·92 (95% CI 0·62 to 1·23) (22 trials involving 
1310 participants) but there was high heterogeneity between trials (I2 = 85%; P < 0·0001). 
There were also improvements in neurological impairment, anxiety and depression. However, 
Research in Context clean file
there was substantial heterogeneity between trials. The Cochrane risk of bias tool 
demonstrated methodological limitations in many of the trials. 
We updated our updated Cochrane review in 2019 used the same methods and identified 63 
trials (recruiting 9168 participants), of which three trials (recruiting 3277 participants) were at 
low risk of bias. These three trials all used fluoxetine, found little or no effect on disability, 
although depression was reduced. The majority (93%) of the patients from low bias trials was 
from the FOCUS trial (n=3127) performed in the UK. Our Cochrane review identified 16 
ongoing SSRI studies (n=4565) for stroke recovery with a median enrolment of 85 
individuals. Two trials – EFFECTS and AFFINITY – represent two-thirds of ongoing 
recruitment. 
Added value of  th is  study 
The EFFECTS trial, which was at low risk of bias, has added a further 1500 patients to the 
three previous trials of fluoxetine (n=3277) that were of low risk of bias, and has confirmed 
that fluoxetine does not improve functional recovery after acute stroke but that it reduces 
depression.  
Impl icat ions of  a l l  the avai lable evidence  
This study is the second largest RCT of fluoxetine for stroke recovery and confirms the 
results from meta-analysis of the low bias studies in the 2019 Cochrane review. Although the 
median NIHSS score of three in EFFECTS is similar to a Swedish stroke population, we 
cannot rule out a benefit in more severe strokes. A further update of the Cochrane review of 
SSRI for stroke recovery, and a pre-planned individual patient data meta-analysis of FOCUS, 
EFFECTS and AFFINITY might identify a more modest effect in subgroups of patients. Until 
these results are known, we would not recommend further fluoxetine trials for stroke 
recovery. 
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although depression was reduced. The majority (93%) of the patients from low bias trials was 
from the FOCUS trial (n=3127) performed in the UK. Our Cochrane review identified 16 
ongoing SSRI studies (n=4565) for stroke recovery with a median enrolment of 85 
individuals. Two trials – EFFECTS and AFFINITY – represent two-thirds of ongoing 
recruitment. 
Added value of th is  study  
The EFFECTS trial, which was at low risk of bias, has added a further 1500 patients to the 
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that fluoxetine does not improve functional recovery after acute stroke but that it reduces 
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results from meta-analysis of the low bias studies in the 2019 Cochrane review. Although the 
median NIHSS score of three in EFFECTS is similar to a Swedish stroke population, we 
cannot rule out a benefit in more severe strokes. A further update of the Cochrane review of 
SSRI for stroke recovery, and a pre-planned individual patient data meta-analysis of FOCUS, 
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 2253 patients excluded 
 1547 not meeting inclusion criteria 
 394 declined to participate 
 312 other reasons 
737 patients analysed intention-to-treat for mRS 
 6 withdraw consent 
 5 did not submit or answered 6 
months central follow-up 
 25 died 
750 patients allocated to fluoxetine 750 patients allocated to placebo 
 
742 patients analysed intention-treat for mRS 
3753 patients assessed for eligibility 
1500 randomised 
 712 submitted or answered 6-month form 
 737 had mRS data available 
 720 submitted or answered 6-month form 
 742 had mRS data available 
 2 withdrew consent 
 17 did not submit or 
answered 6 months  
central follow-up 
 22 died 
748 patients received fluoxetine 
2 withdraw consent 1 withdraw consent, 1 died 
shortly after randomisation  
748 patients received placebo 
Figure 1. CONSORT flow Click here to access/download;Figure;Figure 1 CONSORT
2020_04_11.docx
21·2 29·2 12·8 22·8 6·2.    4·3   3·4
22·9 26·8 14·3 22·1 6·5    4·4   3·0
170 199 106 164 48       33   22
156 216 94 168 46       32   25
Figure 2. Primary outcome Click here to access/download;Figure;Figure 2 Primary
outcome.pdf
 
 Fluoxetine 
(n=750) 
Placebo 
(n=750) 
Sex   
 Women 287 (38%) 288 (38%) 
 Men 463 (62%) 462 (62%) 
Age    
 Age ≤ 70 years 328 (44%) 316 (42%) 
 Age > 70 years 422 (56%) 434 (58%) 
Mean age (SD), years 70·6 (11·3) 71·0 (10·5) 
Ethnicity     
 Asian 1 (0·1%) 6 (0·8%) 
 Black 4 (0·5%) 1 (0·1%) 
 Chinese 0 0 
 White 743 (99%) 738 (98%) 
 Other 2 (0·3%) 5 (0·7%) 
Marital status   
 Married 363 (48%) 394 (53%) 
 Partner 96 (13%) 100 (13%) 
 Divorced or separated 58 (7·7%) 56 (7·5%) 
 Widowed 101 (14%) 87 (11%) 
 Single 120 (16%) 100 (13%) 
 Other 12 (1·6%) 13 (1·7%) 
Living condition before stroke     
 Living with someone else  484 (65%) 467 (62%) 
 Lived alone  266 (36%) 282 (38%) 
 Other 0 1 (0·13%) 
Employment status     
 Full-time employment 158 (21·1%) 154 (20·5%) 
 Part-time employment 30 (4·0%) 38 (5·1%) 
 Retired 544 (72·5%) 538 (71·7%) 
 Unemployed 5 (0·7%) 10 (1·3%) 
 Other 13 (1·7%) 10 (1·3%) 
Independent before stroke 717 (96%) 728 (97%) 
Previous medical history ‡     
 Coronary artery disease 123 (16%) 111 (15%) 
 Ischaemic stroke/TIA  126 (17%) 131 (18%) 
 Diabetes  140 (19%) 159 (21%) 
 Hyponatraemia  11 (1·5%) 8 (1·1%) 
 Intracranial bleed  18 (2·4%) 25 (3·3%) 
 Upper gastrointestinal bleed  23 (3·1%) 30 (4·0%) 
 Bone fractures  221 (30%) 189 (26%) 
 Depression  60 (8·0%) 50 (6·7%) 
Stroke diagnosis     
 Non stroke (final diagnosis) 2 (0·27%) 1 (0·13%) 
Table 1. Patient characteristics at randomisation.
 Ischaemic stroke 662 (88%) 650 (87%) 
 Intracerebral haemorrhage 86 (12%) 99 (13%) 
OCSP classification of ischaemic strokes     
 Total anterior circulation infarct  179 (27%) 185 (29%) 
 Partial anterior circulation infarct 306 (46%) 288 (44%) 
 Lacunar infarct  100 (15%) 103 (16%) 
 Posterior circulation infarct  66 (10%) 60 (9·2%) 
 Uncertain  11 (1·7%) 14 (2·2%) 
Modified TOAST classification of stroke     
 Large artery disease  104 (16%) 88 (14%) 
 Small vessel disease  215 (33%) 205 (32%) 
 Embolism from heart  141 (21%) 162 (25%) 
 Another cause  25 (3·8%) 16 (2·5%) 
 Unknown/uncertain  177 (27%) 179 (27%) 
Predicitive variables     
 Able to walk at time of randomisation 392 (52%) 396 (53%) 
 Able to lift both arms off bed 597 (80%) 577 (77%) 
Predicted 6-month outcome based on Six Simple Variable 
model11 
  
 0∙00 to ≤ 0∙15  147 (20%) 149 (20%) 
 > 0∙15 to 1∙00  603 (80%) 601 (80%) 
Neurological deficits at randomisation   
 Median NIHSS12 (IQR) 3·0 (2·0–6·0) 3·0 (2·0–6·0) 
 Motor deficit * 513 (68%) 533 (71%) 
 Aphasia † 134 (18%) 134 (18%) 
Ongoing depression at randomisation 0 0 
Revascularisation treatment**   
 Intravenous (IV) thrombolysis 167 (23%) 158 (22%) 
 Thrombectomy only 10 (1·4%) 20 (2·7%) 
 IV thrombolysis and thrombectomy 177 (24%) 178 (24%) 
Days between stroke onset and randomisation     
 Median (IQR) 5·0 (4·0–8·0) 5·0 (3·0–8·0) 
 2–8 days 566 (75%) 570 (76%) 
 9–15 days 184 (25%) 1080 (24%) 
 
  n* Fluoxetine (n=750) n* Placebo (n=750) p value 
Stroke Impact Scale17,18      
 Strength  694 75·0 (50·0–93·8) 689 75·0 (50·0–93·8) 0·67 
 Hand ability 690 81·3 (50·0–100) 692 87·5 (50·0–100) 0·99 
 Mobility 696 88·9 (72·2–100) 698 88·9 (72·2–97·2) 1·00 
 Motor † 697 80·3 (60·4–92·8) 695 80·6 (58·1–93·8) 0·95 
 Daily activities  697 87·5 (69·4–97·5) 697 87·5 (67·5–97·5) 0·72 
 Physical function ‡ 697 76·7 (56·3–90·2) 697 77·4 (55·5–91·0) 0·81 
 Memory 696 89·3 (78·6–100) 698 92·9 (82·1–100) 0·0064 
 Communication 695 96·4 (82·1–100) 697 92·1 (85·7–100) 0·83 
 Emotion 695 80·6 (66·7–91·7) 696 76·4 (63·9–88·9) 0·0002 
 Participation 690 65·6 (46·4–89·3) 682 68·8 (43·8–89·3) 0·55 
 Recovery 695 70·0 (50·0–90·0) 695 70·0 (50·0–90·0) 0·79 
NIHSS12  678 1·0 (0·0–2·0) 681 1·0 (0·0–2·0) 0·22 
MoC19  632 26·0 (23·0–28·0) 630 26·0 (23·0–28·0) 0·82 
 
Table 2. Secondary outcomes at 6 months by allocated
treatment.
 Fluoxetine Placebo   
  
  
n (%) n (%) Difference 
(95% CI) 
p value 
Death 25 (3·3%) 22 (2·9%) 0·4 (-0·014 to 0·022) 0·66 
Attempted suicide 1 (0·13%) 1 (0·13%) 0 (-0·0037 to 0·0037) 1 
New depression 54 (7·2%) 81 (10·8%) -3·6 (-0·065 to -0·0071) 0·015 
Antidepressant drug  36 (4·8%) 50 (6·7%) -1·9 (-0·14 to 0·19) 0·76 
Acute coronary events 5 (0·67%) 6 (0·80%) -0·13 (-0·010 to 0·0073) 0·76 
Epileptic seizures 8 (1·07%) 11 (1·47) -0·4 (-0·015 to 0·0073) 0·49 
Uncontrolled diabetes 5 (0·67%) 15 (2·0) -1·33 (-0·025 to -0·0017) 0·024 
Hyponatraemia < 130 mmol/L 11 (1·47%) 1 (0·13%) 1·34 (0·0043 to 0·022) 0·0038 
Fractured bone 28 (3·7) 11 (1·5%) 2·2 (0·0066 to 0·039) 0·0058 
Upper gastrointestinal bleeding 4 (0·53%) 3 (0·40) 0·13 (-0·0056 to 0·0082) 0·71 
New stroke 36 (4·8%) 28 (3·7%) 1·1 (-0·0098 to 0·031) 0·31 
 Ischaemic stroke 31 (4·1%) 26 (3·5%)   
 Intracerebral haemorrhage 5 (0·67%) 1 (0·13%)   
 Subarachnoid Haemorrhage 0 1 (0·13%)   
Thrombotic events     
 Pulmonary embolism 3 (0·40%) 6 (0·80%) -0·4 (-0·012 to 0·0038) 0·32 
 Other thrombotic events 5 (0·67%) 6 (0·80%) -0·13 (-0·010 to 0·0073) 0·76 
Any bleeding events     
 Subdural haematoma 1 (0·13%) 1 (0·13%) 0 (-0·0037 to 0·0037) 1 
 Subarachnoid haemorrhage, 
traumatic 
2 (0·27%) 1 (0·13%) 0·13 (-0·0032 to 0·0059) 0·56 
 Other major bleed 7 (0·93%) 6 (0·80%) 0·13 (-0·0080 to 0·011) 0·78 
 
Table 3. Safety outcomes within 6 months.
